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ABSTRACT 
 Introduction. The present research explores data and analyzes 
molecular mechanisms appraisal of the clinical course of chronic viral hepatitis C, 
registered considering the prognostic significance of the CYP2C9 isoenzyme. The 
aim of the research is to assess the molecular mechanisms of the clinical course 
of CVHC, considering the prognostic significance of the CYP2C9 isoenzyme, 
responsible for the xenobiotic biotransformation system, in representatives of the 
Uzbek population. Materials and methods. 107 patients with chronic viral 
hepatitis C (CVHC) were involved in the research group, further were divided 
into three subgroups to assess the association of polymorphic markers of the 
СУР2С9 genes. The criteria for inclusion in the research were clinical, 
biochemical and instrumental verification of the diagnosis with the 
determination of both the stage and severity of the disease, as well as the 
detection of hepatitis C virus RNA by the AmpliSens® HCV-FRT test system 
detected by polymerase chain reaction (PCR) on a RotorGene 6000 instrument. 
Results and discussion. Research data determined that a relationship was 
established between the mutant allele of CYP2C9 gene polymorphism with more 
favorable course of CVHC. This assumption is also confirmed by the reduced 
frequency of the mutant allele in the subgroup of patients with highly active 
CVHC, which may indicate the protective role of this allele in activating the 
inflammatory process in CVHC. It was revealed that a high level of theoretically 
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expected heterozygosity is the indicator of genetic diversity in the subgroup of 
patients with high active CVHC. Conclusion. The results of the research suggest 
that CYP2C9 gene polymorphism can be considered as a conditionally 
“protective” marker for disease progression and requires further study in a larger 
sample of patients. 
 
Key words: chronic hepatitis, pathogenesis, cytochrome P450, isoenzyme 
CYP2C9, molecular genetic research, gene polymorphism 
 
Introduction 
To date the increase in prevalence and development of chronic viral hepatitis 
C (CVHC) complications remains at the same level both in the developed countries 
and Uzbekistan (1). In addition, the fact that CVHC is one of the main reasons for 
the development of liver cirrhosis and hepatocellular carcinoma remains an 
important aspect (2, 3, 10). It should be noted that in approximately 22% of cases, 
the chronic form of hepatitis C leads to cirrhosis of the liver (4, 11). In connection 
with the foregoing, the issue of the prognosis of morbidity is of particular 
importance. This aspect is considered to be quite relevant and urgent in our region. 
Recently, much attention of specialists has been caused by the possibility of a 
personalized approach to the diseases treatment based on human genetic 
characteristics (13). CYP2C9 is one of the necessary significant isoenzymes of 
cytochrome P450 in the liver (9). It should be noted that the content of the 
CYP2C9 isoenzyme in the liver is 18%, determining its significance in the 
development of liver diseases (5, 12). 
The limited data on exploring of the Uzbek population determined the 
relevance and need for research to identify allelic variants of candidate genes 
associated with the characteristics of the course of CVHC. 
The aim of the study is to assess the molecular mechanisms of the clinical 
course of CVHC, considering the prognostic significance of the CYP2C9 
isoenzyme, responsible for the xenobiotic biotransformation system, in 
representatives of the Uzbek population. 
Material and methods. The main group included 107 patients with CVHC. 
To assess the association of polymorphic markers of the СУР2С9 genes, patients 
with CVHC were divided into three subgroups. The first subgroup included 
patients with a moderate degree of CVHC activity (n=33). The second subgroup 
consisted of patients with a high degree of CVHC activity (n = 37). The third 
subgroup included patients with cirrhosis (n=37). The criteria for study inclusion 
were clinical, biochemical and instrumental verification of the diagnosis with the 
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determination of both the stage and severity of the disease, as well as the 
determination of hepatitis C virus RNA by the AmpliSens® HCV-FRT test system 
identified by polymerase chain reaction (PCR) on a Rotor Gene 6000 instrument. 
As a comparison group, a population control was used, represented by DNA 
samples (n = 81) of conditionally healthy donors (without chronic hepatitis C) 
from the DNA bank of the Research Institute of Hematology and Blood 
Transfusion of the Ministry of Health of the Republic of Uzbekistan. 
The material for molecular genetic research was the peripheral blood of the 
patients. DNA isolation was carried out according to the standard method with 
some modifications and using reagents of the company Interlabservis (Russia). 
Alleles of gene polymorphism were identified using PCR. 
Results and Discussion. The scientific research on the frequency of alleles 
has shown that in both groups of patients and in the group of population control, 
the wild-type allele was predominant. Moreover, in patients with chronic hepatitis 
C, the frequency of occurrence of the “wild” allele (C) of CYP2C9 polymorphism 
was 86.9%, and the mutant allele (T) was 13.1%. The revealed values of the allele 
frequency in the general group of patients did not practically differ from the data of 
the indicators of the studied population (87.6% and 12.3%, respectively, χ2 = 0.05; 
P = 0.83; OR = 1.07; 95% CI 0.58-1.97). Some differences in the indicators were 
revealed in the study of patient samples in accordance with the stage and activity 
of the pathological process. A similar control value for the mutant allele frequency 
was observed in the subgroup of patients with cirrhosis (12.2%; χ2 = 0.002; P = 
0.97; OR = 0.98; 95% CI 0.42-2.28). Simultaneously, an increase in the frequency 
of occurrence of the T allele was noted in the subgroup of patients with high active 
CVHC (19.7%; χ2 = 2.05; P = 0.15; OR = 1.74; 95% CI 0.81- 3.75), and the 
lowest indicator of the frequency of the mutant allele was observed in the second 
group of patients at the peak of the activity of the pathological process (8.1%; χ2 = 
0.002; P = 0.97; OR = 0.98; 95% CI 0 , 42-2.28). Moreover, the difference in the 
incidence rate of the mutant allele was significant both between the first and 
second, and between the second and third (χ2 = 3.99; P = 0.05; OR = 2.78; 95% CI 
0.9907-7.801) subgroups of patients. The increased frequency of the T allele in the 
group of patients with high active chronic hepatitis C is evidence of its possible 
association with an inactive course of the disease. This assumption is also proved 
by the reduced frequency of the mutant allele in the subgroup of patients with 
highly active CVHC, which may indicate the protective role of this allele in 
relation to the activation of the inflammatory process in CVHC. Thus, there is a 
clear connection between the frequencies of occurrence of the mutant allele with a 
more favorable course of CVHC. 
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Besides, the occurrence frequency of the wild type genotype of СYP2С9 
(С/С) polymorphism in the population was studied, it made 75.3%. When 
comparing these data with literature data, there is a slight difference in the 
frequency of occurrence of genotypes (14). Thus, the frequency of occurrence of 
the “wild” genotype of СYP2С9 polymorphism in Turkey was 61.7% (6), in 
Malaysia - 94.0% (7), in Korea - 88.0% (8). A certain difference in the data 
obtained in the research and the literature data are apparently explained by the 
population characteristics of the studied groups. 
The homozygous genotype for the mutant allele (T/T) was not determined 
either in the control or in the main group of patients with CVHC, which may 
indicate its low population incidence. All cases of mutant allele identification were 
represented by a heterozygous genotype (C/T). Moreover, in patients with chronic 
hepatitis C, the frequency of heterozygous genotype occurrence was 26.2%, which 
was comparable with the value of this indicator in the group of control patients 
(24.7%) with an unreliable difference in the result (χ2 = 0.05; P = 0.82; OR = 1.08; 
95% CI0.5565-2.1). A similar control value of the heterozygous genotype 
frequency indicator was also noted in the subgroup of patients with cirrhosis 
(24.3%; χ2 = 0.002; P = 0.97; OR = 0.98; 95% CI 0.3966-2.423). At the same 
time, an increase in the frequency of occurrence of the C / T genotype was noted in 
the subgroup of patients with high active, and the lowest frequency indicator was 
observed in the second group of patients at the peak of the activity of the 
pathological process (16.2%; χ2 = 1.06; P = 0.30; OR = 0.59; 95% CI0.2151-1.62). 
Moreover, the difference in the incidence rate of the heterozygous allele between 
the second and other subgroups of patients was not significant. 
The increased frequency of the C/T genotype in the group of patients with 
high active CVHC indicates that it may be associated with an inactive course of the 
disease. This is also confirmed by the tendency to a decrease in the frequency of 
the heterozygous genotype in the subgroup of patients with highly active chronic 
hepatitis C. However, the unreliability of the difference in the indicators does not 
allow us to unequivocally state the protective role of the C/T genotype with respect 
to the activation of the inflammatory process in CVHC and the connection of this 
genotype with a more favorable course of CVHC. 
The increase in the frequency of the C/T genotype and simultaneously, 
the complete absence of homozygous genotype for the mutant T / T allele can 
be associated both with the selective advantage of the heterozygous 430C> T 
polymorphism of the CYP2C9 gene and the possibility of elimination of the 
mutant homozygous genotype. 
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A study of the frequency of polymorphism CYP2C9*3 gene 1075A> C alleles 
occurrence showed that in the population control group and in the patient 
subgroups, the wild-type allele was predominant. Moreover, the indicators were 
close in value (p> 0.05). Thus, in the control group, the frequency of occurrence of 
the “wild” allele of the studied polymorphism was 93.8%, in patients CVHC - 
90.2%, in patients with high active CVHC - 86.4%, in patients with highly active 
chronic hepatitis C - 94.6%, in patients with cirrhosis of the liver - 89.2%. 
A comparative analysis showed that in the main group of patients with 
chronic hepatitis C, the mutant C allele was more common (9.8%) - compared with 
the population control group (6.2%), but the difference was not significant. When 
analyzing the indicator of the frequency of the mutant allele in accordance with the 
stage of the disease and the activity of the pathological process, a certain range of 
values was noted. The highest frequency of the “C” allele among all the studied 
subgroups was detected in patients with high active chronic hepatitis C (HCV) 
(13.6%). The value of this indicator in the group of patients with cirrhosis was 
lower than in the first group (10.8%; χ2 = 1.55; P = 0.21; OR = 1.84; 95% CI0.70-
4.88) , and the minimum frequency of the mutant allele was recorded in the group 
of patients with actively occurring CVHC. The increased frequency of the “C” 
allele of the 1075A> C polymorphism of the CYP2C9 gene in the group of patients 
with high active CVHB indicates its possible association with the inactive course 
of the disease. This assumption is also confirmed by the reduced frequency of the 
mutant allele in the subgroup of patients with highly active CVHC, which may 
indicate the protective role of this allele in relation to the activation of the 
inflammatory process in CVHC. Thus, there is a clear connection between the 
occurrence of the mutant allele of 1075A> C polymorphism of the CYP2C9 gene 
with a more favorable course of CVHC. 
The frequency of occurrence of the wild type genotype of СYP2С9 
polymorphism (A/A) in the studied population was 87.7%. When comparing these 
data with literature data in other populations, there is a slight difference in the 
frequency of occurrence of genotypes (9). It should be noted that in the study of 
the frequency of the 1075A> C polymorphism genotypes of the CYP2C9 gene in 
the present research, as in the case of the 430C> T polymorphism of the CYP2C9 
gene, no homozygous genotype for the mutant allele (C/C) was determined in any 
of the groups, which most likely indicates its low population occurrence. All cases 
of detection of a mutant allele were represented by a heterozygous genotype (A/C). 
Moreover, in patients with CHVC, the frequency of occurrence of the 
heterozygous genotype was 19.6%, which was 1.6 times more than in the control 
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with an unreliable difference in the indicator (12.3%; χ2 = 1.77; P = 0.18; OR = 
1.73; 95% CI 0.7667-3.92). 
A certain range of values was noted when analyzing the frequency of the 
heterozygous genotype in accordance with the stage of the disease and the activity 
of the pathological process. The highest frequency of the A/C genotype among all 
the studied subgroups was identified in patients with high active CVHC (27.3%), 
and the minimum value of this indicator was noted in patients with an active 
pathological process - the frequency of the heterozygous genotype in these groups 
was 2.5 times. The frequency of the A/C genotype in patients with cirrhosis was 
21.6% and did not have a significant difference with the other studied subgroups. 
The increased frequency of the A/C genotype in the group of patients with high 
active chronic hepatitis C is evidence of its possible association with the inactive 
course of the disease, which is also confirmed by the tendency to decrease the 
frequency of the heterozygous genotype in the subgroup of patients with highly 
active chronic hepatitis C. However, the unreliability of the difference in the 
indicators does not allow to unequivocally state the protective role of the C / T 
genotype with respect to the activation of the inflammatory process in chronic 
hepatitis C and the connection of this genotype with a more favorable course of 
CVHC. 
The results showed the relationship between the mutant “C” allele and the 
heterozygous genotype containing this allele with more favorable course of 
CVHC, cannot be compared with literature data, since studies that have 
investigated the relationship of CYP2C9*3 polymorphism with the pathogenesis 
and progression of CVHC and the severity of liver lesion are not carried out. 
Deviations from the equilibrium state of the 430C> T polymorphism of the 
CYP2C9 gene were also determined by the relative deviation of the expected 
heterozygosity from the observed or by the heterozygous deficiency index (index 
D). At the same time, a positive value of the index D means a deficiency of 
heterozygotes, a negative value means their excess. 
Researching of the expected heterozygosity of the 430C> T polymorphism of 
the CYP2C9*2 gene in the studied groups of relatively healthy individuals and 
patients with CVHC showed that the hexp value in the main group of patients was 
close to the control value (0.227 and 0.217; p> 0.05). Significant differences in the 
indicator were revealed between the subgroups of patients with CVHC. So, the 
highest level of expected heterozygosity was observed in patients with high active 
CVHC (0.316), while in patients with an active process the value of this indicator 
was 2.1 times lower (0.149; p> 0.05). In the group of patients with cirrhosis, the 
hexp value was also lower than in the first group of patients, with an unreliable 
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difference in the indicator (0.214; p> 0.05). The results of the research suggest that 
a high level of theoretically expected heterozygosity is evidence of genetic 
diversity in a subgroup of patients with high active chronic hepatitis C. Moreover, 
in the group of patients with a highly active pathological process, genetic diversity 
is most limited - in comparison with other studied subgroups, which is 
characterized by a low rate of expected heterozygosity. However, the absence of 
significant intergroup differences in hexp values may indicate that the development 
of chronic hepatitis C and the nature of disease course are not related to the level of 
heterozygosity. 
Table 1 
Difference between expected and observed frequency of heterozygosity 
polymorphism 430C>T of the CYP2C9*2 gene 
 
Gene / 
polymorphis
m 
Groups 
 
Observed 
heterozygosity 
 Expected 
heterozygosit
y 
D* Reliability 
Polymorphis
m 430C>T 
CYP2C9 
gene 
Core group 0,262 0,227 0,154 
χ2=2,42, 
р=0,12 
1-subgroup 0,394 0,316 0,247 
χ2=1,99, 
р=0,16 
2-subgroup 0,162 0,149 0,087 
χ2=0,29, 
р=0,59 
3-subgroup 0,243 0,214 0,135 
χ2=0,71, 
р=0,4 
Control group 0,247 0,217 0,138 
χ2=1,61, 
р=0,21 
 
Observed heterozygosity of the 430C> T polymorphism of the CYP2C9 gene 
can judge the measure of genetic variation in the population. An analysis of the 
observed heterozygosity revealed that in the group of population control its value 
exceeded the expected heterozygosity (hobs = 0.247, hexp = 0.217; p> 0.05). A 
small difference between the observed and expected heterozygosity was found in 
the main group of patients (hobs = 0.227, hexp = 0.262; p> 0.05). Among the 
subgroups of patients, the highest value of hobs was noted in the group of patients 
with high active CVHC (0.394), and the lowest - in patients with highly active 
CVHC (0.162). The indicator of hobs in patients with cirrhosis of the liver had an 
intermediate value relative to the indicators of the first and second subgroups 
(0.243) and was close to the value of the control indicator (p> 0.05). This result 
may indicate that the sample of patients with a high proceeding process is 
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characterized by greater genetic variability, while the sample of patients with 
actively occurring chronic hepatitis C is less polymorphic. 
Analysis of the expected heterozygosity showed that the hexp value in the main 
group of patients was 1.5 times higher than the control value (0.177 and 0.116; p> 
0.05). Some differences in the indicator were also revealed between the subgroups 
of patients with CVHC. So, the highest level of expected heterozygosity was 
observed in patients with high active CVHC (0.235), while in patients with an 
active process the value of this indicator was 2.3 times lower (0.102; p> 0.05). In 
the group of patients with cirrhosis, the hexp value was also lower than in the first 
group of patients, with an unreliable difference in the indicator (0.193; p> 0.05). 
The results of the research indicate that a high level of theoretically expected 
heterozygosity is an indicator of genetic diversity in the subgroup of patients with 
high active chronic hepatitis C. Moreover, in the group of patients with a highly 
active pathological process, genetic diversity is most limited in comparison with 
other studied subgroups, as evidenced by the lowest value of expected 
heterozygosity. However, the absence of significant intergroup differences in hexp 
values may indicate that the development of CVHC and the nature of the disease 
course are not related to the level of heterozygosity. 
Conclusions. Thus, according to the research data, a relationship was 
established between the mutant allele of CYP2C9 gene polymorphism with a 
highly active CVHC. This assumption is proved by the reduced frequency of the 
mutant allele in the subgroup of patients with highly active CVHC. A high level of 
theoretically expected heterozygosity is the indicator of genetic diversity in the 
subgroup of patients with high active CVHC. The results obtained indicate that this 
marker can only conditionally be considered as a “protective” factor in relation to 
the progression of the disease and requires further study in a larger group of 
patients. 
The obtained results showed the existence of differences in the frequency of 
occurrence of allelic variants of the studied polymorphisms in patients with 
favorable and unfavorable course of CHCV and various degrees of activity in the 
liver of pathological process caused by infection of CVHC. This fact proves that 
the disorders in regulation of the studied metabolism cytokines and enzymes of 
biotransformation production is a factor influencing the pathogenesis of CHCV. 
 
References 
8
Central Asian Journal of Medicine, Vol. 2020 [2019], Iss. 1, Art. 15
https://uzjournals.edu.uz/tma/vol2020/iss1/15
Central Asian Journal of Medicine 
uzjournals.edu.uz/tma 156 2020#1 
1. Islambekova Z.A. Reducing the prevalence of viral hepatitis B and C in 
Uzbekistan - a component for the prevention of hepatocellular carcinoma // 
Oncology. - 2009. - T. 11, No. 2. - P. 154-157 (in Russian). 
2. Perz J., Armstrong G., Farrington L. et al. The contribution of hepatitis B and 
hepatitis C viral infections to cirrhosis and primary liver cancer worldwide. // 
J. Hepatol., 2006.-№45:- Р.529-538. 
3. Bosch F.X.,Ribes J., Cleries R. et al. Epidemiology of hepatocellular 
carcinoma// Clin Liver Dis.–2005. – Vol. 9, №2. – Р. 191-211. 
4. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus 
infection.// Lancet Infect Dis .-2005.-№5.-Р.558-567. 
5. Pilotto A., Seripa D., Franceschi M. et al. Genetic susceptibility to 
nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of 
cytochrome P450 2C9 polymorphisms.// Gastroenterology.-2007.- №133.- 
Р.465-471. 
6. Aynacioglu A.S., Brockmoller J., Bauer S., et al. Frequency of cytochrome 
P450 CYP2C9 variants in a Turkish population and functional relevance for 
phenytoin // Br. J. Clin. Pharmacol. –1999. –Vol. 483. –P.409-415. 
7. Seng K.C., Gin G.G., Sangkar J.V., Phipps M.E. Frequency of Cytochrome 
P450 2C9 (CYP2C9) Alleles in Three Ethnic Groups in Malaysia // Asia 
Pacific J. of Mol. Biol. and Biotech. –2003. –Vоl 1. –P.83-91. 
8. Bae J.-W., Kim H.-K., Kim J.-H. et al. Allele and genotype frequencies of 
CYP2C9 in a Korean population // Br. J. Clin. Pharmacol. –2005. –Vol. 60. – 
Р.418–422. 
9. Sychev D.A., Stasyak E.V., Ignatiev I.V. et al. Clinical pharmacogenetics of 
the isoenzyme of cytochrome P-450 2C9 // Klin.pharmacol. and ter. - 2005.- 
No. 4.- P.60–63 (in russian). 
10. Blackard J. N., Shire N.J. et al. Acute hepatitis C virus infection:a chronic 
problem//Hepatology.- 2008.– Vol. 47. – Р. 321-331 
11. Albeldawi et al. Hepatitis C virus: prevention, screening, and interpretation of 
assays. ClevelClin// J. Med.– 2010. – Vol. 77. – Р. 16–26. 
12. Gochee P.A., Jonsson J.R., Clouston A.D., et al. Steatosis in chronic hepatitis 
C: association with increased messenger RNA expression of сollagen I, tumor 
necrosis factor-alpha and cytochrome P450 2E1 // J Gastroenterol Hepatol. –
2003, Apr. –18(4). –Р.386-392. 
13. Frye R.F.,Zgheib N.K.,Matzke G.R., et al. Liver disease selectively modulates 
cytochrome P450--mediated metabolism // Clin Pharmacol Ther.–2006 Sep.– 
Vol.80, №3. –Р.235-245.  
9
Azimova et al.: PRINCIPAL ASPECTS OF PATHOGENESIS OF CHRONIC VIRAL HEPATITIS IN U
Published by 2030 Uzbekistan Research Online, 2019
Central Asian Journal of Medicine 
uzjournals.edu.uz/tma 157 2020#1 
14. Carlquist J., Horne B., Muhlestein J. at al. Genotypes of the cytochrome p450 
isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 
conjointly determine stable warfarin dose: a prospective study // Journal of 
Thrombosis and Thrombolysis. – 2006. – Vol. 22. –Р.191-197. 
  
10
Central Asian Journal of Medicine, Vol. 2020 [2019], Iss. 1, Art. 15
https://uzjournals.edu.uz/tma/vol2020/iss1/15
